News Releases

SEATTLE --(BUSINESS WIRE)--May 12, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for

SEATTLE --(BUSINESS WIRE)--May 3, 2022-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate

- In dose escalation across a range of dose regimens, tumor volume reduction was observed in 23% of evaluable participants despite heavily pretreated, advanced solid malignancies - - Monotherapy expansion cohorts with multiple tumor types are planned - NEW ORLEANS --(BUSINESS WIRE)--Apr.

- AACR Investor Event time change to 6:30 p.m. ET - - 21st Annual Needham Virtual Healthcare Conference Presentation April 13 th at 1:30 p.m. ET - SEATTLE --(BUSINESS WIRE)--Apr. 5, 2022-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on

- Novel approach to CD28 to enhance activation of T cells and anti-tumor activity - - Crystallography demonstrates critical interaction between davoceticept’s CD80 domain and PD-L1 - - Data further encourage ongoing davoceticept development, including NEON-1 monotherapy and NEON-2 pembrolizumab

- Alpine to hold Investor Event on Tuesday, April 12 th at 6:00pm ET - SEATTLE --(BUSINESS WIRE)--Mar. 30, 2022-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory

- Execution across three clinical-stage programs and addition of $176 million in committed cash in 2021 from partnerships and financing to further advance pipeline - - Davoceticept monotherapy dose escalation data to be presented at 2022 AACR Annual Meeting - - ALPN-303 phase 1 ongoing; data

- NEON-1 Data Selected for Minisymposium Oral Presentation - SEATTLE --(BUSINESS WIRE)--Mar. 8, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today

-NEON-1 Study of ALPN-202 as a Monotherapy is Unaffected- SEATTLE --(BUSINESS WIRE)--Mar. 7, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today

SEATTLE --(BUSINESS WIRE)--Mar. 1, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate